Company Overview and News

 
Nexgram 4Q net loss widens to RM48.62m

2018-09-28 theedgemarkets
KUALA LUMPUR (Sept 28): Nexgram Holdings Bhd’s net loss for the fourth quarter ended July 31, 2018 expanded to RM48.62 million, from RM8.53 million a year ago.
0096

 
KLCI pares gains, stays up 0.28%

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF

 
KLCI rises 0.46% as select blue chips lift

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI rose 0.46% at mid-morning, tracking gains at the regional markets, lifted by select index-linked blue chips.
HLFBF 7052 GMALF 1082 BATS 4162 0096 5256 5199 GMALY 5139 5258 3301 4715 0900 5208 5819 2836 HIPEF

 
KLCI gains 0.61%, crosses 1,800 level as regional sentiment perks up

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF

 
KLCI rises 0.26%, tracks regional markets

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.26% at mid-morning today, tracking gains at regional markets, lifted by select blue chips.
7084 1023 5258 3026 2836 0096 5256 7199 9334 7123 CIMDF

 
KLCI recovers to erase earlier loss in line with region

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI recovered at midday break, erasing earlier losses, climbing in line with regional peers.
HLFBF UPBMF 7036 1082 BATS 4162 0096 2089 5014 CIMDF 0166 5139 1023 1368 0900 5819 MYPRY 2836

 
KLCI dips 0.39% as select blue chips drag

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI dipped 0.39% at mid-morning, dragged by losses at select index-linked blue chips.
HLFBF PBLOF UPBMF 7036 1082 7113 5681 TPGVF BATS 4162 0096 7087 1295 2089 5256 9334 TGLVY 5139 5258 3301 0900 5819

 
KLCI dips 0.55% in line with regional pull back

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI dipped 0.55% at midday break today, in line with pull back at most regional markets.
4065 7036 7113 5681 TPGVF 0096 9334 6033 7277 7123 5199 TGLVY 5139 5238 PNADF 3026 0900 2836 HIPEF PNAGF 3719

 
KLCI remains under pressure, struggles to defend 1,800-level

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI remained under pressure at midday break today and struggled to defend its 1,800-point level.
HLFBF UPBMF 7036 1082 7113 TPGVF BATS 4162 0096 7087 5168 2089 5014 7123 TGLVY 3026 3867 1368 MYPRY 2836 GEBHF 3719 HRGHY

 
KLCI pares gains, dips below 1,800-level as regional markets slip

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI pared some of its gains at mid-morning today amid some chopping trading as regional markets slipped.
4065 7036 BATS 4162 0096 7087 5014 7123 4863 3867 5819 MYPRY MYTEF 2836 BSMAF GEBHF 3719 1818

 
KLCI lifted by bargain hunting but seen closing lower before the weekend

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): The FBM KLCI made marginal gains today, thanks to bargain-hunting activities on selected index heavy weights.
SPMXY SPMXF 2836 0096

 
KLCI pares loss, broader sentiment stays weak

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI pared some of its losses at midday break today, as the broader sentiment stayed negative, in line with the drop at regional markets.
HLFBF SPMXF 5071 7036 1082 0096 3794 9334 7123 0020 5199 SPMXY 5819 2836 HIPEF 1929

 
Spectre of September ghosts keep haunting KLCI

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI remained in negative zone at mid-morning today as key index-linked blue chips retreated, in tandem with most regional markets.
HLFBF UPBMF 1082 5681 BATS 4162 0096 2089 9334 6033 7123 0020 5199 PNADF 7129 6888 AXXTF HIPEF PNAGF

 
KLCI rises 0.39%, inches closer to 1,800 mark

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI rose 0.39% at the midday break today, as gains in select index-linked blue chips lifted it closer to the 1,800-point mark, tracking the advance at regional markets.
5198 7113 5032 6432 TPGVF BATS 4162 7765 0096 7043 5168 5014 TGLVY 5029 5225 3301 MYPRY Q0F IHHHF HRGHY

 
Nexgram embarks on internal restructuring to streamline businesses

2018-07-19 theedgemarkets
KUALA LUMPUR (July 19): Nexgram Holdings Bhd has embarked upon an internal corporate restructuring (ICR) of its wholly-owned subsidiary Nexgram Land Sdn Bhd and its group of companies to enable a more efficient administration of the organisation.
BSMAF 0096 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...